Adjuvant Durvalumab for Early Stage NSCLC Patients With ctDNA Minimal Residual Disease
Status:
Recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
In this study circulating tumor DNA (ctDNA) blood testing is used to detect the residual
blood cancer. If residual cancer using this blood test is detected there may be at higher
risk of having the cancer return. The study is going to test whether or not the number of
circulating cancer cells detected in the blood can be reduced by administration durvalumab
after the standard treatment if you are tested positive for the residual cancer.